(R)-2-(4'-bromo-biphenyl-4-sulfonyl-amino)-3-methyl-butyric acid,
PD 166793,
PD 169469,
PD-166793,
PD166793,
199850-67-4,
PD 166793,
(S)-2-(4'-Bromo-[1,1'-biphenyl]-4-ylsulfonamido)-3-methylbutanoic acid,
UNII-U855L3SOXD,
PD-166793,
U855L3SOXD,
CHEMBL43152,
(S)-2-(4'-bromobiphenyl-4-ylsulfonamido)-3-methylbutanoic acid,
MMP-2/MMP-3 Inhibitor III, PD166793,
L-Valine, N-((4'-bromo(1,1'-biphenyl)-4-yl)sulfonyl)-,
(S)-2-(4'-Bromo-biphenyl-4-sulfonylamino)-3-methyl-butyric acid,
(S)-2-(4'-bromobiphenyl-4-ylsulfonamido)-3-methyl butanoic acid,
(S)-2-(4′-Bromo-biphenyl-4-sulfonylamino-3-methylbutyric acid),
L-Valine, N-[(4'-bromo[1,1'-biphenyl]-4-yl)sulfonyl]-,
N-[(4'-Bromo[1,1'-biphenyl]-4-yl)sulfonyl]-L-valine,
PD-166793-0000,
SCHEMBL4433724,
BDBM12075,
CTK8B9099,
DTXSID80432421,
GJOCABIDMCKCEG-INIZCTEOSA-N,
HMS3677F07,
ZINC3961071,
ANW-62017,
alpha-arylsulfonylamino carboxylate 2S,
AKOS016004908,
AJ-47541,
DB-066019,
TC-150762,
FT-0774322,
N-(4'-Bromo[1,1'-biphenyl]-4-sulfonyl)-L-valine,
(2S)-2-[[4-(4-bromophenyl)phenyl]sulfonylamino]-3-methyl-butanoic acid,
(2S)-2-{[4-(4-bromophenyl)benzene]sulfonamido}-3-methylbutanoic acid,
CID9887870,
A4438,
A15307,
N-(4/'-Bromo[1,1/'-biphenyl]-4-sulfonyl)-L-valine,
2-[[4-(4-bromophenyl)phenyl]sulfonylamino]-3-methyl-butanoic Acid,